Preclinical evaluation of the theranostic potential of 89Zr/177Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model

被引：0
作者：
Yitian Wu
Tuo li
Xianzhong Zhang
Hongli Jing
Fang Li
Li Huo
机构：
[1] Chinese Academy of Medical Sciences,Medical Science Research Center, Peking Union Medical College Hospital
[2] Chinese Academy of Medical Science and Peking Union Medical College,Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research Beijing Key Laboratory of Molecular Targeted Diagnosis and Thera
来源：
EJNMMI Radiopharmacy and Chemistry | / 9卷
关键词：
Triple negative breast cancer (TNBC); TROP-2; ImmunoPET; Radioimmunotherapy (RIT); Zr; Lu; ADC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 302 条
  • [1] Adams S(2020)Patient-reported outcomes from the Phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer Ann Oncol 31 582-589
  • [2] Diéras V(2014)Trop-2 is a determinant of breast cancer survival PLoS ONE 9 e96993-32
  • [3] Barrios CH(2011)Treatment of HER2-positive breast cancer: current status and future perspectives Nat Rev Clin Oncol 9 16-32
  • [4] Ambrogi F(2011)Treatment of HER2-positive breast cancer: current status and future perspectives Nat Rev Clin Oncol 9 16-1541
  • [5] Fornili M(2021)Sacituzumab govitecan in metastatic triple-negative breast cancer N Engl J Med 384 1529-529
  • [6] Boracchi P(2012)Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer New Engl J Med 366 520-870
  • [7] Trerotola M(2022)ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer Eur J Nucl Med Mol Imaging 49 861-314
  • [8] Relli V(2009)Trop2: a possible therapeutic target for late stage epithelial carcinomas Biochim Biophys Acta 1796 309-583
  • [9] Simeone P(2022)An J Nucl Med 63 573-3593
  • [10] La Sorda R(2023)Zr-labeled PSMA tracer for PET/CT imaging of prostate cancer patients Int J Nanomed 18 3577-884
12345678910